Tumor Burden of Iodine-Avid Bone Metastatic Thyroid Cancer Identified Via F-Sodium Fluoride PET/CT Imaging

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 Jan 26

PMID 38276075

Authors

Carmela Nappi

Emilia Zampella

Valeria Gaudieri

Fabio Volpe

Leandra Piscopo

Carlo Vallone

Leonardo Pace

Andrea Ponsiglione

Simone Maurea

Emanuele Nicolai

Alberto Cuocolo

Michele Klain

Affiliations

Soon will be listed here.

Abstract

Background: Patients with differentiated thyroid cancer (DTC) are referred to radioactive I (RAI) therapy and post-therapy I whole-body scintigraphy (WBS) to identify local and/or remote metastases. Positron emission tomography (PET)/computed tomography (CT) imaging with F-fluoro-D-glucose (FDG) or F-sodium fluoride (NaF) may also be used with these patients for the evaluation of bone metastases. We compared the role of F-NaF PET/CT and F-FDG-PET/CT in patients with DTC and documented bone metastases at post-therapy WBS.

Methods: Ten consecutive DTC patients with iodine avid bone metastasis at post-therapy WBS referred to F-NaF PET/CT and F-FDG PET/CT were studied. The findings of the three imaging procedures were compared for abnormal detection rates and concordance.

Results: At post-therapy I WBS, all patients had skeletal involvement with a total of 21 bone iodine avid lesions. At F-FDG PET/TC, 19 bone lesions demonstrated increased tracer uptake and CT pathological alterations, while 2 lesions did not show any pathological finding. At F-NaF PET/CT, the 19 bone lesions detected at F-FDG PET/TC also demonstrated abnormal tracer uptake, and the other 2 bone iodine avid foci did not show any pathological finding.

Conclusions: In patients with DTC, F-NaF PET/CT did not obtain more information on the metastatic skeletal involvement than post-therapy I WBS and F-FDG PET/CT.

Citing Articles

Current and Emerging Radiotracers and Technologies for Detection of Advanced Differentiated Thyroid Cancer: A Narrative Review.

Pishdad R, Santhanam P Cancers (Basel). 2025; 17(3).

PMID: 39941793 PMC: 11816070. DOI: 10.3390/cancers17030425.

Long-axial-field of view in prostate cancer next generation imaging: the launch pad of theragnostic.

Volpe F, Nappi C, Klain M Eur J Nucl Med Mol Imaging. 2024; 51(7):2134-2136.

PMID: 38351388 DOI: 10.1007/s00259-024-06647-4.

References

Minamimoto R, Loening A, Jamali M, Barkhodari A, Mosci C, Jackson T . Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer. J Nucl Med. 2015; 56(12):1862-8. DOI: 10.2967/jnumed.115.162610. View

Liu Y, Sheng J, Dong Z, Xu Y, Huang Q, Pan D . The diagnostic performance of F-fluoride PET/CT in bone metastases detection: a meta-analysis. Clin Radiol. 2019; 74(3):196-206. DOI: 10.1016/j.crad.2018.12.011. View

Ahmed N, Sadeq A, Marafi F, Gnanasegaran G, Usmani S . Therapy-induced bone changes in oncology imaging with F-sodium fluoride (NaF) PET-CT. Ann Nucl Med. 2022; 36(4):329-339. DOI: 10.1007/s12149-022-01730-y. View

Hawkins R, Choi Y, Huang S, Hoh C, Dahlbom M, Schiepers C . Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med. 1992; 33(5):633-42. View

Choudhury P, Gupta M . Differentiated thyroid cancer theranostics: radioiodine and beyond. Br J Radiol. 2018; 91(1091):20180136. PMC: 6475953. DOI: 10.1259/bjr.20180136. View

Pacini F, Basolo F, Bellantone R, Boni G, Cannizzaro M, De Palma M . Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies. J Endocrinol Invest. 2018; 41(7):849-876. DOI: 10.1007/s40618-018-0884-2. View

Dadgar H, Norouzbeigi N, Jokar N, Zareizadeh J, Gholamrezanezhad A, Ahmadzadehfar H . Comparison of F-NaF Imaging, Tc-MDP Scintigraphy, and F-FDG for Detecting Bone Metastases. World J Nucl Med. 2022; 21(1):1-8. PMC: 9056122. DOI: 10.1055/s-0042-1748154. View

Schirrmeister H, Buck A, Guhlmann A, Reske S . Anatomical distribution and sclerotic activity of bone metastases from thyroid cancer assessed with F-18 sodium fluoride positron emission tomography. Thyroid. 2001; 11(7):677-83. DOI: 10.1089/105072501750362754. View

Wang H, Dai H, Li Q, Shen G, Shi L, Tian R . Investigating F-FDG PET/CT Parameters as Prognostic Markers for Differentiated Thyroid Cancer: A Systematic Review. Front Oncol. 2021; 11:648658. PMC: 8158293. DOI: 10.3389/fonc.2021.648658. View

10.

Zacho H, Ravn S, Ejlersen J, Fledelius J, Dolliner P, Nygaard S . Observer experience and accuracy of 18F-sodium-fluoride PET/CT for the diagnosis of bone metastases in prostate cancer. Nucl Med Commun. 2022; 43(6):680-686. DOI: 10.1097/MNM.0000000000001550. View

11.

Minamimoto R, Hancock S, Schneider B, Chin F, Jamali M, Loening A . Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med. 2015; 57(4):557-62. DOI: 10.2967/jnumed.115.168393. View

12.

Haugen B, Alexander E, Bible K, Doherty G, Mandel S, Nikiforov Y . 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015; 26(1):1-133. PMC: 4739132. DOI: 10.1089/thy.2015.0020. View

13.

Beheshti M, Mottaghy F, Paycha F, Behrendt F, Van den Wyngaert T, Fogelman I . (18)F-NaF PET/CT: EANM procedure guidelines for bone imaging. Eur J Nucl Med Mol Imaging. 2015; 42(11):1767-1777. DOI: 10.1007/s00259-015-3138-y. View

14.

Klain M, Nappi C, Nicolai E, Romeo V, Piscopo L, Giordano A . Comparison of simultaneous F-2-[18F] FDG PET/MR and PET/CT in the follow-up of patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2020; 47(13):3066-3073. DOI: 10.1007/s00259-020-04938-0. View

15.

Cook G, Goh V . Molecular Imaging of Bone Metastases and Their Response to Therapy. J Nucl Med. 2020; 61(6):799-806. DOI: 10.2967/jnumed.119.234260. View

16.

Fourquet A, Rosenberg A, Mena E, Shih J, Turkbey B, Blain M . A Comparison of F-DCFPyL, F-NaF, and F-FDG PET/CT in a Prospective Cohort of Men with Metastatic Prostate Cancer. J Nucl Med. 2021; 63(5):735-741. DOI: 10.2967/jnumed.121.262371. View

17.

Lee J, Park Y, Jeon Y, Kim K, Lee J, Hong S . Clinical value of dual-phase F-18 sodium fluoride PET/CT for diagnosing bone metastasis in cancer patients with solitary bone lesion. Quant Imaging Med Surg. 2020; 10(11):2098-2111. PMC: 7547267. DOI: 10.21037/qims-20-607. View

18.

Ueda C, Duarte P, de Castroneves L, Coura-Filho G, Sado H, Sapienza M . Comparison of F-NaF PET/CT with Other Imaging Methods in the Detection of Bone Metastases in Patients with Medullary Thyroid Cancer: a Report of a Series of 31 Cases. Nucl Med Mol Imaging. 2020; 54(6):281-291. PMC: 7704988. DOI: 10.1007/s13139-020-00666-3. View

19.

Park P, Raynor W, Sun Y, Werner T, Rajapakse C, Alavi A . F-Sodium Fluoride PET as a Diagnostic Modality for Metabolic, Autoimmune, and Osteogenic Bone Disorders: Cellular Mechanisms and Clinical Applications. Int J Mol Sci. 2021; 22(12). PMC: 8234710. DOI: 10.3390/ijms22126504. View

20.

Broos W, van der Zant F, Wondergem M, Knol R . Accuracy of 18F-NaF PET/CT in bone metastasis detection and its effect on patient management in patients with breast carcinoma. Nucl Med Commun. 2018; 39(4):325-333. DOI: 10.1097/MNM.0000000000000807. View